CLDX
Celldex Therapeutics Inc.

9,720
Mkt Cap
$1.53B
Volume
1.19M
52W High
$30.50
52W Low
$14.40
PE Ratio
-6.80
CLDX Fundamentals
Price
$23.00
Prev Close
$23.57
Open
$23.66
50D MA
$26.16
Beta
1.10
Avg. Volume
661,305.70
EPS (Annual)
-$2.45
P/B
2.55
Rev/Employee
$37,741.93
$911.89
Loading...
Loading...
News
all
press releases
Celldex Therapeutics Teases Key Barzolvolimab Phase 3 Updates, New Data at Guggenheim Summit
Celldex Therapeutics (NASDAQ:CLDX) executives used a presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline upcoming clinical milestones for barzolvolimab across multiple...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Celldex Therapeutics Breaks Below 200-Day Moving Average - Notable for CLDX
In trading on Thursday, shares of Celldex Therapeutics, Inc. (Symbol: CLDX) crossed below their 200 day moving average of $23.76, changing hands as low as $23.61 per share. Celldex Therapeutics, Inc...
Nasdaq News: Markets·11d ago
News Placeholder
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the company, MarketBeat.com...
MarketBeat·15d ago
News Placeholder
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Large Growth in Short Interest
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling...
MarketBeat·28d ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 7.5% - Here's Why
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 7.5% - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Celldex Therapeutics SVPs Engage In Heavy Transactions
Key PointsFreddy A. Jimenez directly sold 4,166 shares for a transaction value of $121,210 on Dec. 4, 2025...
Nasdaq News: Markets·1mo ago
News Placeholder
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Analysts
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat...
MarketBeat·1mo ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% Higher - Should You Buy?
Celldex Therapeutics (NASDAQ:CLDX) Shares Up 4.1% - Here's Why...
MarketBeat·2mo ago
News Placeholder
Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX
Simplify Asset Management Inc. purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the third quarter, according to its most recent Form 13F filing with...
MarketBeat·2mo ago
News Placeholder
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9%
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling...
MarketBeat·2mo ago
<
1
2
...
>

Latest CLDX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.